Return to Today's science sparks archives

2012-07-02

Fig 2d. BAX/BAK DKO cells were exposed to 10 µg/ml Tm in the presence of cell culture media containing 10% serum (top panel) or pretreated in media containing 0.5% serum (bottom panel).

Fig 2d. BAX/BAK DKO cells were exposed to 10 µg/ml Tm in the presence of cell culture media containing 10% serum (top panel) or pretreated in media containing 0.5% serum (bottom panel).
  • Zamorano S, Rojas-Rivera D, Lisbona F, Parra V, Court FA, Villegas R, Cheng EH, Korsmeyer SJ, Lavandero S, Hetz C

  • PLoS One. 2012;7(6):e37782.
Open Access button

2012-07-03

Fig 1a. Incontinence procedures reported by certifying urologists as percentage of total number per year.

Fig 1a. Incontinence procedures reported by certifying urologists as percentage of total number per year.
  • Poon SA, Silberstein JL, Savage C, Maschino AC, Lowrance WT, Sandhu JS

  • J Urol. 2012 Jul;188(1):205-10.

2012-07-03

Fig 1. AlignNemo Overview.

Fig 1. AlignNemo Overview.
  • Ciriello G, Mina M, Guzzi PH, Cannataro M, Guerra C

  • PLoS One. 2012;7(6):e38107.
Open Access button

2012-07-05

Fig 6. Evaluation of microtubule organization.

Fig 6. Evaluation of microtubule organization.
  • Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R

  • Exp Hematol. 2012 Jul;40(7):564-74.

2012-07-06

Fig 1.  An intensity-modulated radiation therapy plan for medullary thyroid cancer.

Fig 1. An intensity-modulated radiation therapy plan for medullary thyroid cancer.
  • Brierley J, Sherman E

  • Semin Radiat Oncol. 2012 Jul;22(3):254-62.

2012-07-09

Fig 3. Effect of expressing dominant-negative mutant of Cx26 in sister neurons.

Fig 3. Effect of expressing dominant-negative mutant of Cx26 in sister neurons.
  • Li Y, Lu H, Cheng PL, Ge S, Xu H, Shi SH, Dan Y

  • Nature. 2012 May 2;486(7401):118-21.

2012-07-10

Fig 1. CTLA-4 external domain confers Treg suppression.

Fig 1. CTLA-4 external domain confers Treg suppression.
  • Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, Adams A, Granger L, Kruhlak M, Lindsten T, Thompson CB, Feigenbaum L, Singer A

  • Blood. 2012 May 31;119(22):5155-63.

2012-07-11

Fig 5B. PGT modulates wound healing rates in diabetic mice. Wound area as a function of time, analyzed using ImageJ software.

Fig 5B. PGT modulates wound healing rates in diabetic mice. Wound area as a function of time, analyzed using ImageJ software.
  • Syeda MM, Jing X, Mirza RH, Yu H, Sellers RS, Chi Y

  • Am J Pathol. 2012 Jul;181(1):334-46.

2012-07-12

Fig 1. Autophagy proteins involved in autophagy and macroendocytic degradation pathways.

Fig 1. Autophagy proteins involved in autophagy and macroendocytic degradation pathways.
  • Florey O, Overholtzer M

  • Trends Cell Biol. 2012 Jul;22(7):374-80.

2012-07-13

Fig 1B. Chromosome Y haplogroup tree and frequency distribution in control subjects of European ancestry in Stage I. b The circle plots show frequencies for haplogroups with a derived frequency of 5% or higher in different colors for each Stage I cohort (remaining haplogroups are combined in one group shown in black)

Fig 1B. Chromosome Y haplogroup tree and frequency distribution in control subjects of European ancestry in Stage I. b The circle plots show frequencies for haplogroups with a derived frequency of 5% or higher in different colors for each Stage I cohort (remaining haplogroups are combined in one group shown in black)
  • Wang Z, Parikh H, Jia J, Myers T, Yeager M, Jacobs KB, Hutchinson A, Burdett L, Ghosh A, Thun MJ, Gapstur SM, Ryan Diver W, Virtamo J, Albanes D, Cancel-Tassin G, Valeri A, Cussenot O, Offit K, Giovannucci E, Ma J, Stampfer MJ, Michael Gaziano J, Hunter DJ, Dutra-Clarke A, Kirchhoff T, Alavanja M, Freeman LB, Koutros S, Hoover R, Berndt SI, Hayes RB, Agalliu I, Burk RD, Wacholder S, Thomas G, Amundadottir L

  • Hum Genet. 2012 Jul;131(7):1173-85.
Open Access button

2012-07-16

Fig 2. Complementary branches of the TGF-β/Smad pathway in embryonic stem cells.

Fig 2. Complementary branches of the TGF-β/Smad pathway in embryonic stem cells.
  • Massagué J, Xi Q

  • FEBS Lett. 2012 Jul 4;586(14):1953-8.

2012-07-17

Fig 6. Annual screening should produce greater than 20% reduction in lung cancer–specific mortality. There is an increase in detected cancers in the LDCT arm during the active screening period, but not after the start of the observation period (arrow).

Fig 6. Annual screening should produce greater than 20% reduction in lung cancer–specific mortality. There is an increase in detected cancers in the LDCT arm during the active screening period, but not after the start of the observation period (arrow).
  • Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, Macmahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ

  • J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8.

2012-07-18

Fig 1. Isodense beam distribution showing example of typical isodose distribution using eight angles equally spaced over 200°–240° sector encompassing ipsilateral lung. Area within green lines depicts target volume.

Fig 1. Isodense beam distribution showing example of typical isodose distribution using eight angles equally spaced over 200°–240° sector encompassing ipsilateral lung. Area within green lines depicts target volume.
  • Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, Rimner A, Flores R, Rusch V

  • Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83.

2012-07-19

Fig 1a. Scatter plot graphs showing gene expression correlation between fresh-frozen (X-axis) and formalin fixed paraffin-embedded (Y-axis) specimens in patient matched samples #13-control.

Fig 1a. Scatter plot graphs showing gene expression correlation between fresh-frozen (X-axis) and formalin fixed paraffin-embedded (Y-axis) specimens in patient matched samples #13-control.
  • Morrogh M, Andrade VP, Patil AJ, Qin LX, Mo Q, Sakr R, Arroyo CD, Brogi E, Morrow M, King TA

  • J Surg Res. 2012 Jul;176(1):121-32.

2012-07-20

Graphical Abstract.

Graphical Abstract.
  • Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagué J, Kang Y

  • Cancer Cell. 2011 Dec 13;20(6):701-14.

2012-07-23

Fig 1. Response to initial therapy definitions (6–24 months).

Fig 1. Response to initial therapy definitions (6–24 months).
  • Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM

  • Clin Endocrinol (Oxf). 2012 Jul;77(1):132-8.

2012-07-24

Fig 1. Family pedigree of a patient with a BRCA1 mutation and pancreatic adenocarcinoma.

Fig 1. Family pedigree of a patient with a BRCA1 mutation and pancreatic adenocarcinoma.
  • Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM

  • Oncologist. 2011;16(10):1397-1402.

2012-07-25

Fig 1. Population-averaged changes in eGFR after minimally invasive PN for patients given (gray line) and not given (black line) mannitol, adjusting for interval from surgery (modeled with splined terms), preoperative eGFR, American Society of Anesthesiologists score (1-2 vs 3-4), ischemia time, estimated blood loss, age, sex, year of surgery, and total nephrometry score (4-6, 7-9, 10-11).

Fig 1. Population-averaged changes in eGFR after minimally invasive PN for patients given (gray line) and not given (black line) mannitol, adjusting for interval from surgery (modeled with splined terms), preoperative eGFR, American Society of Anesthesiologists score (1-2 vs 3-4), ischemia time, estimated blood loss, age, sex, year of surgery, and total nephrometry score (4-6, 7-9, 10-11).
  • Power NE, Maschino AC, Savage C, Silberstein JL, Thorner D, Tarin T, Wong A, Touijer KA, Russo P, Coleman JA

  • Urology. 2012 Apr;79(4):821-6.

2012-07-26

Fig 2a. The 10-yr predicted risk reduction for metastasis among men treated by radical prostatectomy versus watchful waiting in the presence of a competing risk (death from other causes) for men with Gleason 6 (orange line), Gleason 7 (blue dashed line), or Gleason 8 (green line) disease.

Fig 2a. The 10-yr predicted risk reduction for metastasis among men treated by radical prostatectomy versus watchful waiting in the presence of a competing risk (death from other causes) for men with Gleason 6 (orange line), Gleason 7 (blue dashed line), or Gleason 8 (green line) disease.
  • Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L

  • Eur Urol. 2012 Aug;62(2):204-9.

2012-07-27

Fig 1. Schematic representation of the axial section of prostate and periprostatic fasciae at midprostate with three different dissection planes (intrafascial [red line], interfascial [green line], and extrafascial [blue line]).

Fig 1. Schematic representation of the axial section of prostate and periprostatic fasciae at midprostate with three different dissection planes (intrafascial [red line], interfascial [green line], and extrafascial [blue line]).
  • Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C

  • Eur Urol. 2012 Aug;62(2):261-72.

2012-07-30

Fig 1e. Immunofluorescence of epidermal whole mounts stained for YFP (green) and MHC-II (red) from untreated and tamoxifen-treated YFP mice. (Scale bar, 30 μm.)

Fig 1e. Immunofluorescence of epidermal whole mounts stained for YFP (green) and MHC-II (red) from untreated and tamoxifen-treated YFP mice. (Scale bar, 30 μm.)
  • Bobr A, Igyarto BZ, Haley KM, Li MO, Flavell RA, Kaplan DH

  • Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10492-7.

2012-07-31

Fig 2. Abdominal lymphatic nodes collecting lymph from the right (green) and left (red) adrenal glands, based on previously published anatomic studies.

Fig 2. Abdominal lymphatic nodes collecting lymph from the right (green) and left (red) adrenal glands, based on previously published anatomic studies.
  • Gaujoux S, Brennan MF

  • Surgery. 2012 Jul;152(1):123-32.

2012-08-01

Fig 1c. Fluorescent in situ hybridization (FISH) analysis confirming KRAS amplification in resistant (DiFi-R) but not parental DiFi cells.

Fig 1c. Fluorescent in situ hybridization (FISH) analysis confirming KRAS amplification in resistant (DiFi-R) but not parental DiFi cells.
  • Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A

  • Nature. 2012 Jun 28;486(7404):532-6.

2012-08-02

Figure S2. Experimental Design for Acute DT-Mediated Ablation of CNS1-Sufficient Treg Cells in Heterozygous Foxp3CNS1KO/DTR Females, Related to Figure 4(A) Timeline of DT treatments (arrowheads) and mating.

Figure S2. Experimental Design for Acute DT-Mediated Ablation of CNS1-Sufficient Treg Cells in Heterozygous Foxp3CNS1KO/DTR Females, Related to Figure 4(A) Timeline of DT treatments (arrowheads) and mating.
  • Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY

  • Cell. 2012 Jul 6;150(1):29-38.

2012-08-03

Fig. 2. Pleural fluid cytology material positive for adenocarcinoma, ThinPrep slide.

Fig. 2. Pleural fluid cytology material positive for adenocarcinoma, ThinPrep slide.
  • Hasanovic A, Ang D, Moreira AL, Zakowski MF

  • Lung Cancer. 2012 Aug;77(2):299-305.

2012-08-06

Fig 4. Representative grade 4 esophageal complication after spine radiosurgery, showing the role of iatrogenic manipulation in development of high-grade toxicity.

Fig 4. Representative grade 4 esophageal complication after spine radiosurgery, showing the role of iatrogenic manipulation in development of high-grade toxicity.
  • Cox BW, Jackson A, Hunt M, Bilsky M, Yamada Y

  • Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e661-7.

2012-08-07

Fig 2. These images of tumor sections from Patients 1 and 2 depict positive CD163 and CD52 immunostaining in both tumors. (A-C)

Fig 2. These images of tumor sections from Patients 1 and 2 depict positive CD163 and CD52 immunostaining in both tumors. (A-C)
  • Shukla N, Kobos R, Renaud T, Teruya-Feldstein J, Price A, McAllister-Lucas L, Steinherz P

  • Cancer. 2012 Aug 1;118(15):3719-24.

2012-08-08

Fig 4. Polarized contact dermatoscopic image of amelanotic melanoma with crystalline/chrysalis structures and polymorphous vessels.

Fig 4. Polarized contact dermatoscopic image of amelanotic melanoma with crystalline/chrysalis structures and polymorphous vessels.
  • Balagula Y, Braun RP, Rabinovitz HS, Dusza SW, Scope A, Liebman TN, Mordente I, Siamas K, Marghoob AA

  • J Am Acad Dermatol. 2012 Aug;67(2):194.e1-8.

2012-08-09

Figure 5. ALKF1174L Induces Expression of Endogenous Murine MYCN (A) Heat map representing the top 50 upregulated genes (corrected p value < 0.05, fold change ≥ 2.0) in ALKF1174L/MYCN tumors compared with MYCN tumors.

Figure 5. ALKF1174L Induces Expression of Endogenous Murine MYCN (A) Heat map representing the top 50 upregulated genes (corrected p value < 0.05, fold change ≥ 2.0) in ALKF1174L/MYCN tumors compared with MYCN tumors.
  • Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE

  • Cancer Cell. 2012 Jul 10;22(1):117-30.

2012-08-10

Fig 3. Item information curves of all neuroticism items.

Fig 3. Item information curves of all neuroticism items.
  • Li Y, Baser R

  • Stat Med. 2012 Aug 15;31(18):2010-26.

2012-08-13

Fig 1a. Typical conformal three-dimensional plan for a locally advanced adenocarcinoma arising in the pancreatic head.

Fig 1a. Typical conformal three-dimensional plan for a locally advanced adenocarcinoma arising in the pancreatic head.
  • Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA

  • Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1355-64.

2012-08-14

Fig 2. Dose–volume histograms of selected structures by treatment modality.

Fig 2. Dose–volume histograms of selected structures by treatment modality.
  • Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA

  • Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1580-6.

2012-08-15

Fig 2. Pharmacology of 17-allyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(3′-iodo)benzamido]morphinan.

Fig 2. Pharmacology of 17-allyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(3′-iodo)benzamido]morphinan.
  • Majumdar S, Subrath J, Le Rouzic V, Polikar L, Burgman M, Nagakura K, Ocampo J, Haselton N, Pasternak AR, Grinnell S, Pan YX, Pasternak GW

  • J Med Chem. 2012 Jul 26;55(14):6352-62.

2012-08-16

Fig 1. 
CONSORT diagram. Bev, bevacizumab; Cis, cisplatin; Gem, gemcitabine.

Fig 1. CONSORT diagram. Bev, bevacizumab; Cis, cisplatin; Gem, gemcitabine.
  • Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE

  • J Clin Oncol. 2012 Jul 10;30(20):2509-15.

2012-08-17

Fig. 1. Flow chart of the systematic review. LRP = laparoscopic radical prostatectomy;

Fig. 1. Flow chart of the systematic review. LRP = laparoscopic radical prostatectomy;
  • Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F

  • Eur Urol. 2012 Sep;62(3):418-30.

2012-08-20

Fig 3. HOXB1 Protein Structure, Conservation, and Molecular Modeling. (E) The sulfur atom of mutant Arg5Cys residue (red C5) of the HOXB1 homeodomain would interact with the oxygen atom of T11 base of the DNA via one hydrogen bond at 6.0Å.

Fig 3. HOXB1 Protein Structure, Conservation, and Molecular Modeling. (E) The sulfur atom of mutant Arg5Cys residue (red C5) of the HOXB1 homeodomain would interact with the oxygen atom of T11 base of the DNA via one hydrogen bond at 6.0Å.
  • Webb BD, Shaaban S, Gaspar H, Cunha LF, Schubert CR, Hao K, Robson CD, Chan WM, Andrews C, Mackinnon S, Oystreck DT, Hunter DG, Iacovelli AJ, Ye X, Camminady A, Engle EC, Jabs EW

  • Am J Hum Genet. 2012 Jul 13;91(1):171-9.

2012-08-21

Fig 3. IHC assay results of the node visualized in Fig. 2. (A) VEGF, (B) Ki-67, (C) HIF-1α, (D) CA-IX, (E) H&E, and (F) HPV.

Fig 3. IHC assay results of the node visualized in Fig. 2. (A) VEGF, (B) Ki-67, (C) HIF-1α, (D) CA-IX, (E) H&E, and (F) HPV.
  • Jansen JF, Carlson DL, Lu Y, Stambuk HE, Moreira AL, Singh B, Patel SG, Kraus DH, Wong RJ, Shaha AR, Shah JP, Shukla-Dave A

  • Oral Oncol. 2012 Aug;48(8):717-22.

2012-08-22

Fig 1. N-back performance data. Task performance data by group for low (0-back and 1-back) and high (2-back and 3-back) working memory load.

Fig 1. N-back performance data. Task performance data by group for low (0-back and 1-back) and high (2-back and 3-back) working memory load.
  • McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ

  • J Clin Oncol. 2012 Jul 10;30(20):2500-8.

2012-08-23

Fig 2. Survival by human epidermal growth factor receptor 2 (HER2) status and sites of metastasis.

Fig 2. Survival by human epidermal growth factor receptor 2 (HER2) status and sites of metastasis.
  • Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N

  • J Clin Oncol. 2012 Jul 10;30(20):2545-51.

2012-08-24

Fig 1. MRI findings in a 68-year-old woman with progressive dementia and previous history of primary central nervous system lymphoma treated with high-dose methotrexate chemotherapy and whole-brain radiotherapy (45 Gy).

Fig 1. MRI findings in a 68-year-old woman with progressive dementia and previous history of primary central nervous system lymphoma treated with high-dose methotrexate chemotherapy and whole-brain radiotherapy (45 Gy).
  • Graber JJ, Omuro A.

  • Curr Opin Neurol. 2011 Dec;24(6):633-40.

2012-08-24

Fig 1a. Isolation of full-length h-Scc2/4 and derivatives. (A) Schematic diagram of h-Scc2 showing conserved residues among species and h-Scc2 derivatives expressed and purified in insect cells.

Fig 1a. Isolation of full-length h-Scc2/4 and derivatives. (A) Schematic diagram of h-Scc2 showing conserved residues among species and h-Scc2 derivatives expressed and purified in insect cells.
  • Bermudez VP, Farina A, Higashi TL, Du F, Tappin I, Takahashi TS, Hurwitz J

  • Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9366-71.

2012-08-28

Fig 5. E2F7 binds to a subset of E2F targets during senescence. (B) Position weight matrix of the motif significantly enriched in the DNA associated with E2F7.

Fig 5. E2F7 binds to a subset of E2F targets during senescence. (B) Position weight matrix of the motif significantly enriched in the DNA associated with E2F7.
  • Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X, Lowe SW

  • Genes Dev. 2012 Jul 15;26(14):1546-57.

2012-08-29

Fig 3. Approaches to erasing tissue-specific epigenetic memory and evaluating the resulting pluripotent stem cells.

Fig 3. Approaches to erasing tissue-specific epigenetic memory and evaluating the resulting pluripotent stem cells.
  • Tobin SC, Kim K

  • FEBS Lett. 2012 Aug 31;586(18):2874-81.

2012-08-30

Fig 1a. Biopsies of the pelvic recurrence from Patient 1 show a high-grade undifferentiated spindle cell malignant neoplasm, involving small bowel serosa and abdominal biopsies.

Fig 1a. Biopsies of the pelvic recurrence from Patient 1 show a high-grade undifferentiated spindle cell malignant neoplasm, involving small bowel serosa and abdominal biopsies.
  • Garg K, Park KJ, Soslow RA

  • Int J Gynecol Pathol. 2012 Sep;31(5):423-8.

2012-08-31

Fig 1. Microscopic features of EGFR/KRAS-mutant “SQCC” with a revised diagnosis of AD-SQC or solid adenocarcinoma.

Fig 1. Microscopic features of EGFR/KRAS-mutant “SQCC” with a revised diagnosis of AD-SQC or solid adenocarcinoma.
  • Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M

  • Clin Cancer Res. 2012 Feb 15;18(4):1167-76.

2012-09-04

Fig 4. The relative volume of craniofacial resections in the Memorial Sloan–Kettering Cancer Center (MSKCC) between 1973 and 2005.

Fig 4. The relative volume of craniofacial resections in the Memorial Sloan–Kettering Cancer Center (MSKCC) between 1973 and 2005.
  • Gil Z, Fliss DM, Cavel O, Shah JP, Kraus DH

  • Head Neck. 2012 Sep;34(9):1212-7.

2012-09-05

Fig 1. Non–intensive care unit central line–associated bloodstream infection rates. In 2009, the National Healthcare Safety Network pooled rate for inpatient wards was 1.14 per 1,000 catheter-days.

Fig 1. Non–intensive care unit central line–associated bloodstream infection rates. In 2009, the National Healthcare Safety Network pooled rate for inpatient wards was 1.14 per 1,000 catheter-days.
  • Son CH, Daniels TL, Eagan JA, Edmond MB, Fishman NO, Fraser TG, Kamboj M, Maragakis LL, Mehta SA, Perl TM, Phillips MS, Price CS, Talbot TR, Wilson SJ, Sepkowitz KA

  • Infect Control Hosp Epidemiol. 2012 Sep;33(9):869-74.

2012-09-06

Fig 1. Pathophysiology of (A) mammalian target of rapamycin (mTOR) inhibitor–induced hyperlipidemia and (B) phosphoinositide 3- kinase–Akt–mTOR pathway inhibitor–induced hyperglycemia. LPL, lipoprotein lipase; TG, triglyceride; VDL, very low density lipoprotein.

Fig 1. Pathophysiology of (A) mammalian target of rapamycin (mTOR) inhibitor–induced hyperlipidemia and (B) phosphoinositide 3- kinase–Akt–mTOR pathway inhibitor–induced hyperglycemia. LPL, lipoprotein lipase; TG, triglyceride; VDL, very low density lipoprotein.
  • Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL

  • J Clin Oncol. 2012 Aug 10;30(23):2919-28.

2012-09-07

Fig 4. Optical and histologic detection of viral replication using vaccinia marker genes.

Fig 4. Optical and histologic detection of viral replication using vaccinia marker genes.
  • Haddad D, Chen CH, Carlin S, Silberhumer G, Chen NG, Zhang Q, Longo V, Carpenter SG, Mittra A, Carson J, Au J, Gonen M, Zanzonico PB, Szalay AA, Fong Y

  • PLoS One. 2012;7(8):e41647.
Open Access button

2012-09-10

Fig 3. Transforming activity of ZIC2 assayed by foci formation in MEFs.

Fig 3. Transforming activity of ZIC2 assayed by foci formation in MEFs.
  • Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, Porcu L, Bussani C, D'Incalci M, Erba E, Romano M, Cattoretti G, Katsaros D, Koff A, Luzzatto L

  • Clin Cancer Res. 2012 Aug 15;18(16):4313-4324.

2012-09-11

Fig 1a. Representation of De Novo Events in Testicular Germ Cell Tumors: an amplification in 7q11.22.

Fig 1a. Representation of De Novo Events in Testicular Germ Cell Tumors: an amplification in 7q11.22.
  • Stadler ZK, Esposito D, Shah S, Vijai J, Yamrom B, Levy D, Lee YH, Kendall J, Leotta A, Ronemus M, Hansen N, Sarrel K, Rau-Murthy R, Schrader K, Kauff N, Klein RJ, Lipkin SM, Murali R, Robson M, Sheinfeld J, Feldman D, Bosl G, Norton L, Wigler M, Offit K

  • Am J Hum Genet. 2012 Aug 10;91(2):379-83.

2012-09-12

Fig. 2. Proteins interacting with AID at S regions during CSR.

Fig. 2. Proteins interacting with AID at S regions during CSR.
  • Vuong BQ, Chaudhuri J

  • Semin Immunol. 2012 Aug;24(4):264-72.

2012-09-13

Fig 1. Esophagobronchial fistula arising from an esophageal diverticulum.

Fig 1. Esophagobronchial fistula arising from an esophageal diverticulum.
  • Zolotarevsky E, Kwon Y, Bains M, Schattner M

  • Ann Thorac Surg. 2012 Sep;94(3):e69-70.

2012-09-14

Figure 4. Expression of ASXL1 in ASXL1-Null Leukemic Cells Results in Global Increase in H3K27me2/3.

Figure 4. Expression of ASXL1 in ASXL1-Null Leukemic Cells Results in Global Increase in H3K27me2/3.
  • Abdel-Wahab O, Adli M, Lafave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL

  • Cancer Cell. 2012 Aug 14;22(2):180-93.

2012-09-17

Fig 1. Microbiota effects on immunity.

Fig 1. Microbiota effects on immunity.
  • Ubeda C, Pamer EG

  • Trends Immunol. 2012 Sep;33(9):459-66.

2012-09-18

Figure S7. Histological Confirmation of Bone Metastasis and Validation of P-Smad Staining of Bone Sections.

Figure S7. Histological Confirmation of Bone Metastasis and Validation of P-Smad Staining of Bone Sections.
  • Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG

  • Cell. 2012 Aug 17;150(4):764-79.

2012-09-19

Fig 6. IL-22R Is Expressed in Intestinal Crypts, and Intestinal Stem Cells Are Targets of GVHD(A and B) LP→B6 BMT was performed with T cell-depleted marrow alone or with marrow and T cells.

Fig 6. IL-22R Is Expressed in Intestinal Crypts, and Intestinal Stem Cells Are Targets of GVHD(A and B) LP→B6 BMT was performed with T cell-depleted marrow alone or with marrow and T cells.
  • Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR

  • Immunity. 2012 Aug 24;37(2):339-50.

2012-09-20

Fig 6. Phosphosignaling Analysis of Primary Leukemic Blasts Harboring NUP214-ABL1, BCR-JAK2, and STRN3-JAK2

Fig 6. Phosphosignaling Analysis of Primary Leukemic Blasts Harboring NUP214-ABL1, BCR-JAK2, and STRN3-JAK2
  • Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG

  • Cancer Cell. 2012 Aug 14;22(2):153-66.

2012-09-21

Fig 2. Dr Warshaw's reprogramming along the “pancreatic axis”.

Fig 2. Dr Warshaw's reprogramming along the “pancreatic axis”.
  • Alsina J, Lafemina J

  • Surgery. 2012 Sep;152(3 Suppl 1):S71-3.

2012-09-24

Fig 1. Selection process for studies included in the meta-analysis.

Fig 1. Selection process for studies included in the meta-analysis.
  • Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME

  • Eur J Cancer. 2012 Feb;48(3):340-6.

2012-09-25

Fig 4. Survival after resection stratified by margin status.

Fig 4. Survival after resection stratified by margin status.
  • Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, Dematteo RP, Gonen M, Endo I, Jarnagin WR

  • J Am Coll Surg. 2012 Sep;215(3):343-55.

2012-09-26

Fig 1a. The small protein ubiquitin is attached to a cysteine residue on E2 conjugating enzymes as an intermediate step before being transferred to other proteins through a process that is stimulated by E3 ligase enzymes.

Fig 1a. The small protein ubiquitin is attached to a cysteine residue on E2 conjugating enzymes as an intermediate step before being transferred to other proteins through a process that is stimulated by E3 ligase enzymes.
  • Lima CD, Schulman BA

  • Nature. 2012 Sep 6;489(7414):43-4.

2012-09-27

Fig 1. Receiver operating characteristic curves.

Fig 1. Receiver operating characteristic curves.
  • Lughezzani G, Zorn KC, Budäus L, Sun M, Lee DI, Shalhav AL, Zagaya GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Cronin A, Vickers AJ, Karakiewicz PI

  • Eur Urol. 2012 Oct;62(4):590-6.

2012-09-28

Cell-type–specific sequence models can predict cell-type–specific binding at loci that are DNase accessible in both cell lines.

Cell-type–specific sequence models can predict cell-type–specific binding at loci that are DNase accessible in both cell lines.
  • Arvey A, Agius P, Noble WS, Leslie C

  • Genome Res. 2012 Sep;22(9):1723-34.
Open Access button

2012-10-01

Summary of canonical and splicing-mediated miRNA pathways.

Summary of canonical and splicing-mediated miRNA pathways.
  • Ladewig E, Okamura K, Flynt AS, Westholm JO, Lai EC

  • Genome Res. 2012 Sep;22(9):1634-45.